Skip to main content

Table 4 Relationship between tumor burden and outcome in the literature

From: Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers

 Period of recruitmentNumber of patientsMedian number of biopsy coresMedian follow-upOutcome
Grann et al., 1998 [16]1988–1994103NA3 years5-year bPFS =
LT < 10 mm: 74%
LT > 10 mm: 36%
(p = 0.011, univariate / p = 0.15 multivariate)
Merrick et al., 2002 [57]1995–1999262 (111 with exclusive brachytherapy)6 (2–15)38.6 months5-year bPFS = 92.5%
PPB < 34%: 96.6%
PPB 34–50%: 92.9%
PPB > 50%: 84.8%
(p = 0.017)
PPB not associated with bPFS within each risk group.
Merrick et al., 2004 [58]1995–2001413 (197 with exclusive brachytherapy)NA52 months7-year bPFS =
PPB < 34%: 99.4%
PPB 34–50%: 94.3%
PPB > 50%: 89.2%
(p = 0.002)
Rossi et al., 2006 [17]1997–19991081261 months5-year bPFS = 87%
PPB < 50%: 95%
PPB > 50%: 63%
(p < 0.0001)
Guzzo et al., 2008 [18]1992–20022456.8 (1–18)52.8 months5-year bPFS: 82%
PPB < 27%: 89.1%
PPB > 27%: 73.8%
(p = 0.011)
Merrick et al., 2008 [59]1995–2004145 5.8 years9-year bPFS = 97.1%
PPB = predictor of bPFS in multivariate analysis.
Potters et al., 2008 [19]1992–20001449NA82 months12-year bPFS = 78%
PPB independently associated with bPFS in the multivariate analysis (p = 0.037).
Taira et al., 2011 [20]1995–20061656 (831 with exclusive brachytherapy)NA7 years12-year bPFS = 95.6%
PPB > 34%: 98%
PPB 34–50%: 93%
PPB > 50%: 91.5%
(p < 0.001)
Hill et al., 2015 [60]1998–2012846125.59 yearsBiochemical failures: 62 (7.3%)
Failures: PPB = 32.8%
Non failures: PPB = 34.9%
NS
Martell et al., 2017 [61]2003–20132608NA4,7 yearsEstimated 7-year-bPFS = 93%
PPB not associated with bPFS.
Present study2006–201328212 (5–32)61 monthsBiochemical failures: 20 (7.1%)
Failures: PPB =17%
Non failures: PPB = 17%
NS
  1. Abbreviations: bPFS biochemical Progression Free Survival, PPB Percentage of Positive Biopsies, LT length of tumor, NS Non significant